DexaFit Dx is developing an artificial intelligence-based early detection test that utilizes non-invasive imaging technology to identify chronic diseases before symptoms appear. This approach addresses the challenge of late diagnosis in conditions like heart disease and cancer, which account for over two-thirds of annual deaths.
Funding
Funding not disclosed
Founders
Product
Problem
Many chronic diseases, such as heart disease and cancer, often go undetected until they reach advanced stages, leading to poorer outcomes and higher mortality rates. Current screening methods can be risky, invasive, unreliable, or too costly for widespread, regular use. This results in delayed diagnoses and missed opportunities for early intervention.
Solution
DexaFit Dx is developing an AI-powered early detection test designed to identify major chronic diseases before symptoms manifest. By leveraging non-invasive imaging technologies and artificial intelligence, the test aims to detect disease risks at an earlier, more treatable stage. The company's approach integrates with existing healthcare technologies to provide a simple, safe, and affordable solution for early disease detection. This enables proactive intervention and improved patient outcomes by identifying potential health issues before they become critical.
Target Audience
The primary target audience includes healthcare providers, hospitals, and individuals seeking proactive and early detection of chronic diseases.
Features
- AI-driven analysis of non-invasive imaging data for early detection of chronic disease risks.
- Integration with established healthcare technologies for seamless implementation.
- Focus on detecting common chronic diseases, including heart disease and cancer.
- Aims to provide a cost-effective and safe alternative to traditional screening methods.